At least one pre-registered multi-site replication trial of psilocybin's extinction-without-relapse-prevention mechanism in substance use disorder will be launched (registered on ClinicalTrials.gov or equivalent) before June 30, 2027.

Scientists will register a new multi-site research study (publicly announced on ClinicalTrials.gov, the official trial registry) focused on understanding exactly how psilocybin helps people stop using cocaine or opioids. They'll pre-register their methods to prevent researchers from changing their approach after seeing results. This matters because it builds solid science on the mechanism (the actual biological how) rather than just whether it works.

Clean mechanistic findings with grant-fundable ambiguity reliably generate follow-up trials. NIDA's funding cycles, university research incentives, and the availability of existing psilocybin research infrastructure all support this. The 5-studies claim in the original was not independently falsifiable without defining 'mechanistic follow-up'; replaced with the cleaner, verifiable pre-registered trial criterion. Confidence is moderate given funding timelines.